Skip to Main Content

Paper Details

Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
Eur Urol
93
2019
, -catenin, -, -catenin, Enzalutamide, Metastatic Castration-resistant Prostate Cancer, Metastatic castration-resistant prostate cancer, PARTICIPANTS, PATIENT, RB1, RB1 DNA, RB1 DNA alterations, RNA, Wnt/, catenin, enzalutamide, gene set, key driver gene, mCRPC, men, metastatic castration-resistant prostate cancer, patients, transcriptome RNA, whole-
Author NameAffiliation
Rahul AggarwalHelen Diller Family Comprehensive Cancer Center, University of California San Francisco
George V ThomasKnight Cancer Institute, Oregon Health & Science University
Tomasz M BeerKnight Cancer Institute, Oregon Health & Science University
David A QuigleyHelen Diller Family Comprehensive Cancer Center, University of California San Francisco
Adam FoyeHelen Diller Family Comprehensive Cancer Center, University of California San Francisco
Jiaoti HuangDuke University
Paul LloydHelen Diller Family Comprehensive Cancer Center, University of California San Francisco
Eric LuKnight Cancer Institute, Oregon Health & Science University
Matthew B RettigUniversity of California Los Angeles, USA VA Greater Los Angeles Healthcare System
Martin E GleaveUniversity of British Columbia
Christopher P EvansUniversity of California Davis
Lawrence D TrueUniversity of Washington
Primo N LaraUniversity of California Davis
Kim N ChiUniversity of British Columbia
Robert E ReiterUniversity of California Los Angeles
Christopher A MaherWashington University in St. Louis
Christopher A MaherWashington University in St. Louis
Felix Y FengHelen Diller Family Comprehensive Cancer Center, University of California San Francisco
Eric J SmallHelen Diller Family Comprehensive Cancer Center, University of California San Francisco
Joshi J AlumkalKnight Cancer Institute, Oregon Health & Science University
  • 1 - 20

Datasets